Section 09

The Field

Public enforcement and research records in the same industry and city. Each row is a source. What it establishes, and what it does not, stay on the row. None of these rows is his operative report.

Stryker Research Institute, Scripps Health, Scripps Clinic Medical Group, and SCORE are not one noun. A TSRI grant settlement is not Scripps Green. A Rejuvenate modular-neck payout is not a Secur-Fit / Trident / Biolox card. Persona IQ is a knee. His surgeries were hips. Public misconduct in this industry is documented. It is not his operative report.

Each row is a public record with a source. Click through.

2018

FDA / device industry

The Bleeding Edge

Kirby Dick / Amy Ziering Netflix documentary on the medical-device industry, 510(k) clearance, and patient harm from devices including metal hips.

Establishes. A widely distributed film argues that device regulation can fail patients. Former FDA commissioner David Kessler is quoted in contemporaneous coverage on a system that does not work for devices.

Does not. Does not name Hooman, Walker, or his Stryker Secur-Fit / Trident / Biolox parts. A film is context, not his operative report.

Netflix · The Bleeding Edge

3 Nov 2014 / May 2017

Stryker Orthopaedics

Rejuvenate and ABG II modular-neck settlements

Stryker announced a U.S. settlement for patients who had revision surgery on recalled Rejuvenate Modular-Neck and/or ABG II stems. Later coverage of a second program cited a global cost on the order of $2 billion.

Establishes. Stryker has paid very large sums over specific recalled modular-neck hips. Kickbacks and recalls are not imaginary categories.

Does not. Does not identify Hooman’s 2015/2017 parts. Staff lists on his file name conventional Secur-Fit / Trident / Biolox — a different product line. A Rejuvenate settlement is not his implant card.

Stryker IR · 3 Nov 2014 settlement

8 Dec 2014

OtisMed / Stryker

OtisKnee unapproved cutting guides

DOJ: OtisMed and its former CEO pleaded guilty to distributing knee cutting guides after FDA rejection. Stryker and OtisMed paid about $79.56 million. DOJ stated the criminal conduct occurred before Stryker’s 2009 acquisition and without Stryker’s prior knowledge.

Establishes. An acquired Stryker subsidiary sold unapproved knee devices. FDA rejection is not a theoretical risk.

Does not. Does not concern hip stems. Does not prove off-label modification of Hooman’s hips. Knee cutting guides are not a THA.

DOJ · OtisMed news release

11 Sep 2020

The Scripps Research Institute

$10 million NIH grant-charging settlement

TSRI agreed to pay $10 million to resolve False Claims Act allegations that it charged NIH grants for non-grant time (new applications, teaching, admin). No admission of liability in the institute’s public characterization.

Establishes. The research institute that shares the Scripps name has a public False Claims Act settlement.

Does not. TSRI is not Scripps Green Hospital and not Scripps Clinic Medical Group. Grant-time accounting is not an implant. Do not fuse the entities.

Times of San Diego · TSRI $10M

19 Jan 2018

Scripps Health

$1.5 million unsupervised physical-therapy billing

Scripps Health paid $1.5 million to resolve allegations it billed Medicare/TRICARE for PT by therapists without billing privileges and without required physician supervision. Whistleblower Suzanne Forrest. Scripps described a technical billing error and did not concede the care was not delivered.

Establishes. The hospital system has a public False Claims Act settlement about unsupervised billing.

Does not. Does not mention orthopedics, Walker, or implants. Billing privileges are not telemetry.

HHS OIG · Scripps Health $1.5M

2 Feb 2026

Peer-reviewed field / D’Lima

Sensor-integrated hip and knee prostheses (Frontiers)

A February 2026 review traces instrumented implants, cites D’Lima’s Scripps Clinic tibial-tray work (2005–2007), and notes Persona IQ as an FDA-cleared sensor-enabled *knee* in 2021.

Establishes. Instrumented implants are real, published, and associated with Scripps Clinic research. D’Lima is in that literature.

Does not. A research knee tray and a 2021 commercial smart knee are not Hooman’s 2015/2017 hip parts. Walker’s 2025 sentences still say standard Stryker, no chips. The field existing is why the file stays open. It is not the device in his bone.

Frontiers · 2 Feb 2026 review

10–14 Mar 2025

Johnson & Johnson MedTech

AAOS 2025, San Diego — digital orthopaedics

J&J MedTech press copy for the AAOS 2025 annual meeting in San Diego describes a ‘new era of digital orthopaedics’ — implants, techniques, data-driven technologies.

Establishes. The industry was publicly selling ‘digital orthopaedics’ in San Diego in March 2025, the same season his theory crystallized.

Does not. A trade-show press release does not name his surgeon or his parts. Calendar overlap is overlap.

J&J MedTech · AAOS 2025

Dec 1987 / 2 Aug 1994

Johnson & Johnson Interventional Systems

Palmaz-Schatz Balloon-Expandable Stent — public calendar

First human iliac implant May 1987, Freiburg. First human coronary implant December 1987, São Paulo. J&J licensed in 1986. U.S. iliac approval 1991; U.S. coronary PMA P900043 on 2 August 1994 after BENESTENT and STRESS. Palmaz writes that coronary experience already existed in multiple cities outside the U.S. by 1991.

Establishes. An early-1990s introduction outside the United States was possible. U.S. coronary approval in 1994 is not a worldwide start date. Tehran hospital histories date angioplasty expansion to 1370 SH (March 1991–March 1992).

Does not. Does not name Hooman, Ghasemi, Valeix, or Imam Khomeini Hospital. Possibility is not a shipping record with his name on it.

Federal Register · PMA P900043